Towards Healthcare
Alzheimer Therapeutics Market to Soar USD 12.07 Bn by 2034

Alzheimer Therapeutics Market Size, Drug Pipeline Developments and Investment Trends

Based on market forecasts, the alzheimer’s therapeutics sector will expand from USD 5.24 billion in 2024 to USD 12.07 billion by 2034, experiencing a CAGR of 8.7%. In 2024, North America led the market, while Asia-Pacific is set for the fastest growth ahead. Cholinesterase inhibitors dominated by product, but pipeline drugs are expected to grow the quickest. Hospital pharmacies held the top spot among end-users, with e-commerce projected for strong future growth.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Alzheimer's Therapeutics Market Assessment

  • Overview
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce
  • Global Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America Alzheimer's Therapeutics Market Assessment

  • Overview
  • North America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • North America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Europe Alzheimer's Therapeutics Market Assessment

  • Overview
  • Europe Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Europe Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Asia Pacific Alzheimer's Therapeutics Market Assessment

  • Overview
  • Asia Pacific Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Asia Pacific Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Middle East and Africa Alzheimer's Therapeutics Market Assessment

  • Overview
  • Middle East and Africa Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • Middle East and Africa Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

South America Alzheimer's Therapeutics Market Assessment

  • Overview
  • South America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by Product Type (2021 – 2033)
    • Cholinesterase Inhibitors
      • Donepezil
      • Galantamine
      • Rivastigmine
    • NMDA Receptor Antagonist
    • Combination Drugs
    • Pipeline Drugs
  • South America Alzheimer's Therapeutics Market Size Value (US$) and Volume (Billion Tons), by End User (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • E-commerce

Company Profiles

  • Biogen Inc.
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Eli Lilly and Company
  • Eisai Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc
  • AbbVie Inc.

Conclusion & Recommendations

  • Insight Code: 5130
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: April 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

Alzheimers disease is a progressive brain disorder that affects memory, thinking skills, and behavior. It is the most common cause of dementia among older adults.

The driving factors of the Alzheimers therapeutics market include the aging population and ongoing innovation in treatment approaches.

North America leads the market for Alzheimers therapeutics due to its robust healthcare infrastructure and high prevalence of the disease, particularly in the United States and Canada.

World Health Organization, National Institute of Health, Food and Drug Administration, Centers for Disease Control and Prevention and Alzheimers Association.